Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new target...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellinato, Francesco, Chiricozzi, Andrea, Piaserico, Stefano, Targher, Giovanni, Gisondi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/
https://www.ncbi.nlm.nih.gov/pubmed/36361639
http://dx.doi.org/10.3390/ijms232112849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/
https://www.ncbi.nlm.nih.gov/pubmed/36361639
http://dx.doi.org/10.3390/ijms232112849

Ejemplares similares